Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2024/6142211 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832543802251804672 |
|---|---|
| author | Gisle Langslet Thomas Nyström Dorte Vistisen Bendix Carstensen Emilie Toresson Grip Paula Casajust Giorgi Tskhvarashvili Fabian Hoti Riho Klement Kristina Karlsdotter Mikko Tuovinen Anne Pernille Ofstad Maria Lajer Christina Shay Lisette Koeneman Soulmaz Fazeli Farsani Leo Niskanen Sigrun Halvorsen |
| author_facet | Gisle Langslet Thomas Nyström Dorte Vistisen Bendix Carstensen Emilie Toresson Grip Paula Casajust Giorgi Tskhvarashvili Fabian Hoti Riho Klement Kristina Karlsdotter Mikko Tuovinen Anne Pernille Ofstad Maria Lajer Christina Shay Lisette Koeneman Soulmaz Fazeli Farsani Leo Niskanen Sigrun Halvorsen |
| author_sort | Gisle Langslet |
| collection | DOAJ |
| description | Conclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries. |
| format | Article |
| id | doaj-art-c69b0f920a1f4c00a227f3b29b7c11c9 |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-c69b0f920a1f4c00a227f3b29b7c11c92025-02-03T11:28:29ZengWileyJournal of Diabetes Research2314-67532024-01-01202410.1155/2024/6142211Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) StudyGisle Langslet0Thomas Nyström1Dorte Vistisen2Bendix Carstensen3Emilie Toresson Grip4Paula Casajust5Giorgi Tskhvarashvili6Fabian Hoti7Riho Klement8Kristina Karlsdotter9Mikko Tuovinen10Anne Pernille Ofstad11Maria Lajer12Christina Shay13Lisette Koeneman14Soulmaz Fazeli Farsani15Leo Niskanen16Sigrun Halvorsen17Lipid ClinicDepartment of Clinical Science and EducationClinical EpidemiologyClinical EpidemiologyReal World Data and Data AnalyticsReal-World Data and Data AnalyticsGlobal Database Studies, Real World SolutionsGlobal Database Studies, Real World SolutionsGlobal Database Studies, Real World SolutionsMarket AccessGlobal Medical AffairsType 2 Diabetes and MetabolismGlobal Integrated EvidenceGlobal Integrated EvidenceDiabetes Global Medical AffairsGlobal Integrated EvidencePäijät-Häme Joint Authority for Health and WellbeingDepartment of CardiologyConclusion: Empagliflozin initiation was associated with a significantly reduced risk of ACM, HHF, CVM, and ESRD compared with initiation of DPP-4i in patients with T2D when examining routine clinical practice data from Nordic countries.http://dx.doi.org/10.1155/2024/6142211 |
| spellingShingle | Gisle Langslet Thomas Nyström Dorte Vistisen Bendix Carstensen Emilie Toresson Grip Paula Casajust Giorgi Tskhvarashvili Fabian Hoti Riho Klement Kristina Karlsdotter Mikko Tuovinen Anne Pernille Ofstad Maria Lajer Christina Shay Lisette Koeneman Soulmaz Fazeli Farsani Leo Niskanen Sigrun Halvorsen Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study Journal of Diabetes Research |
| title | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study |
| title_full | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study |
| title_fullStr | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study |
| title_full_unstemmed | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study |
| title_short | Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study |
| title_sort | empagliflozin use is associated with lower risk of all cause mortality hospitalization for heart failure and end stage renal disease compared to dpp 4i in nordic type 2 diabetes patients results from the emprise empagliflozin comparative effectiveness and safety study |
| url | http://dx.doi.org/10.1155/2024/6142211 |
| work_keys_str_mv | AT gislelangslet empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT thomasnystrom empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT dortevistisen empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT bendixcarstensen empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT emilietoressongrip empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT paulacasajust empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT giorgitskhvarashvili empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT fabianhoti empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT rihoklement empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT kristinakarlsdotter empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT mikkotuovinen empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT annepernilleofstad empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT marialajer empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT christinashay empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT lisettekoeneman empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT soulmazfazelifarsani empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT leoniskanen empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy AT sigrunhalvorsen empagliflozinuseisassociatedwithlowerriskofallcausemortalityhospitalizationforheartfailureandendstagerenaldiseasecomparedtodpp4iinnordictype2diabetespatientsresultsfromtheempriseempagliflozincomparativeeffectivenessandsafetystudy |